Milwaukee County Fights to Hold Pharmaceutical Manufacturers and Distributors Responsible for Creating Opioid Epidemic
National law firm Baron & Budd to lead litigation against drug companies, alleging costs of...READ MORE
National Law Firm Marks Occasion by Raising Awareness of Potentially Dangerous Diabetes Medications
DALLAS (Nov. 13, 2015) – The national law firm of Baron & Budd is marking World Diabetes Day, and also working to raise awareness regarding potentially dangerous drugs designed to help those fighting the disease. These medications include Invokana, Invokamet, Glyxambi, Xigduo XR, Farxiga and Jardiance, which have been linked to severe health issues such as diabetic ketoacidosis, kidney disease and others. World Diabetes Day is Saturday, Nov. 14.
According to the International Diabetes Foundation, World Diabetes Day is the largest diabetes awareness campaign in the world. In 2014, more than 100 countries held events on World Diabetes Day. This year’s theme is “Healthy Living and Diabetes,” with events dedicated to helping educate people on the warning signs associated with the disease. In addition, events will also be held to inform people on what to do if they are diagnosed with diabetes, and who to turn to for help in managing and controlling the disease.
Many Type 2 diabetes patients have turned to drugs such as Invokana, Invokamet, Glyxambi and others in an effort to control some of the complications associated with diabetes. These drugs are known as sodium-glucose cotransporter-2, or SGLT2, inhibitors. They are designed to work with the kidneys to remove excess sugar from a diabetic patient’s bloodstream by removing it through urination, thus lowering the level of sugar in the blood.
A protein called SGLT2 is produced by the body to prevent the loss of sugar. However, diabetics have too much sugar in their blood, leading to severe complications. SGLT2 inhibitors are designed to keep the protein from performing its function.
In May 2015, the U.S. Food and Drug Administration issued a Safety Communication stating that SGLT2 inhibitors pose a risk of diabetic ketoacidosis. This condition can be extremely serious, as it can significantly increase the amount of acid in the bloodstream. This occurs when a person does not have enough insulin in order to ensure the body has enough glucose. When the body detects this problem, it begins to burn fatty acids, producing waste products known as ketone bodies. These ketone bodies trigger ketoacidosis. Vomiting, abdominal pain, dehydration, fatigue and confusion are some of the symptoms. These symptoms should not be ignored. If not treated, diabetic ketoacidosis can be fatal.
In addition, SGLT2 inhibitors have been linked to kidney damage due to a buildup of ketone bodies.
“World Diabetes Day is extremely important, because it helps to raise awareness of a disease that has affected far too many people,” said Russell Budd, president and managing shareholder of the national law firm of Baron & Budd. “It is also important to note, however, that people already struggling with this disease should not also have to suffer severe complications from the medications that are supposed to help them.”
Please contact the national law firm of Baron & Budd if you or someone close to you has suffered harm after taking an SGLT2 inhibitor. Call 1 (866) 700-8994 to learn more about your potential legal options.
ABOUT BARON & BUDD, P.C.
The law firm of Baron & Budd, P.C., with offices in Dallas, Baton Rouge, New Orleans, Austin and Los Angeles, is a nationally recognized law firm with a nearly 40-year history of “Protecting What’s Right” for people, communities and businesses harmed by negligence. Baron & Budd’s size and resources enable the firm to take on large and complex cases. The firm represents individuals and government and business entities in areas as diverse as dangerous pharmaceuticals and medical devices, environmental contamination, the Gulf oil spill, financial fraud, overtime violations, deceptive advertising, automotive defects, trucking accidents, nursing home abuse, and asbestos-related illnesses such as mesothelioma.